Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Quince Therapeutics Inc shares valued at $53,900 were purchased by Thye Dirk on Aug 30 ’24. At $0.70 per share, Thye Dirk acquired 77,000 shares. The insider’s holdings grew to 843,941 shares worth approximately $0.87 million following the completion of this transaction.
Also, Thye Dirk purchased 77,500 shares, netting a total of over 53,475 in proceeds. Following the buying of shares at $0.69 each, the insider now holds 766,941 shares.
Before that, Ryan Charles S. had added 48,387 shares to its account. In a trade valued at $31,452, the PRESIDENT bought Quince Therapeutics Inc shares for $0.65 each. Upon closing the transaction, the insider’s holdings increased to 48,387 shares, worth approximately $0.13 million.
As published in their initiating research note from Oppenheimer on March 24, 2025, Quince Therapeutics Inc [QNCX] has been an Outperform and the price target has been revised to $10.
Analyzing QNCX Stock Performance
During the last five days, there has been a drop of approximately -4.63%. Over the course of the year, Quince Therapeutics Inc shares have dropped approximately -44.92%. Shares of the company reached a 52-week high of $2.0397 on 01/06/25 and a 52-week low of $0.9319 on 04/11/25. A 50-day SMA is recorded $1.2448, while a 200-day SMA reached $1.2605.
Support And Resistance Levels for Quince Therapeutics Inc (QNCX)
According to the 24-hour chart, there is a support level at 1.0067, which, if violated, would cause prices to drop to 0.9833. In the upper region, resistance lies at 1.0567. The next price resistance is at 1.0833. RSI (Relative Strength Index) is 38.68 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0477, which suggests the price will decrease in the coming days. Percent R is at 77.78%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
